Table 2 Patient characteristics between different DAA according to different genotype
From: Hepatitis C micro-elimination through the retrieval strategy of patients lost to follow-up
All (N = 323) | Grazoprevir + elbasvir (Zepatier) (N = 48)(14.9%) | Glecaprevir + pibrentasvir (Maviret) (N = 83)(25.7%) | Sofosbuvir + ledipasvir (Harvoni) (N = 32)(9.9%) | Sofosbuvir + velpatasvir (Epclusa) (N = 160)(49.5%) | P value | |
|---|---|---|---|---|---|---|
Male | 162 (50.5%) | 16 (33.3%) | 52 (62.7%) | 15 (46.9%) | 79 (50.0%) | 0.013 |
Age (years) | 59.0 ± 11.28 | 61.02 ± 10.93 | 57.87 ± 11.92 | 55.81 ± 12.82 | 59.62 ± 10.62 | 0.144 |
Genotype 1a | 28(8.7%) | 0 (0%) | 11 (13.3%) | 2 (6.3%) | 15 (9.4%) | 0.069 |
Genotype 1b | 131(40.6%) | 48 (100%) | 21 (25.3%) | 8 (25.0%) | 54 (33.8%) | 0.000 |
Genotype 2 | 133(41.2%) | 0 (0%) | 42 (50.6%) | 19 (59.4%) | 72 (45.0%) | 0.000 |
Genotype 3 | 3(0.9%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (100%) | 0.379 |
Genotype 6 | 18(5.6%) | 0 (0%) | 6 (7.2%) | 3 (9.4%) | 9 (5.6%) | 0.246 |
Genotype Mix | 10(3.1%) | 0 (0%) | 3 (3.6%) | 0 (0%) | 7 (4.4%) | 0.32 |
RNA (IU/mL)(106) | 4.39 ± 5.96 | 3.04 ± 4.82 | 4.89 ± 6.6 | 2.93 ± 3.63 | 4.78 ± 6.24 | 0.098 |
INR | 1.08 ± 0.11 | 1.09 ± 0.21 | 1.09 ± 0.07 | 1.1 ± 0.08 | 1.07 ± 0.08 | 0.447 |
WBC (x/μL)(103) | 6.15 ± 1.97 | 6.18 ± 1.97 | 6.16 ± 1.80 | 5.88 ± 1.81 | 6.20 ± 2.09 | 0.879 |
Hb (g/dL) | 13.66 ± 2.06 | 13.30 ± 1.71 | 13.32 ± 2.38 | 13.85 ± 1.67 | 13.93 ± 2.01 | 0.075 |
Platelet (x/μL)(103) | 206.95 ± 68.52 | 213.18 ± 70.62 | 200.29 ± 66.58 | 196.90 ± 75.67 | 210.58 ± 67.65 | 0.500 |
Albumin (g/dL) | 4.3 ± 0.39 | 4.33 ± 0.29 | 4.23 ± 0.44 | 4.4 ± 0.28 | 4.30 ± 0.41 | 0.163 |
AST (IU/L) | 53.55 ± 45.91 | 43.71 ± 27.71 | 50.47 ± 41.26 | 50.44 ± 37.64 | 58.76 ± 53.18 | 0.189 |
ALT (IU/L) | 64.13 ± 67.22 | 47.15 ± 40.77 | 64.34 ± 66.76 | 65.22 ± 70.36 | 68.92 ± 72.73 | 0.275 |
T-Bilirubin (mg/dL) | 0.72 ± 0.41 | 0.63 ± 0.3 | 0.68 ± 0.37 | 0.81 ± 0.47 | 0.74 ± 0.44 | 0.162 |
AFP (ng/mL) | 21.26 ± 156.39 | 12.36 ± 55.86 | 5.19 ± 7.37 | 6.75 ± 9.40 | 35.52 ± 220.73 | 0.438 |
Fibrosis F3 | 42 (13.0%) | 11 (22.9%) | 9 (10.8%) | 3 (9.4%) | 19 (11.9%) | 0.170 |
Fibrosis F4 | 37(11.5%) | 2 (4.2%) | 15 (18.1%) | 3 (9.4%) | 17 (10.7%) | 0.098 |
EOT | 321 (99.4%) | 47 (97.9%) | 83 (100%) | 32 (100%) | 159 (99.4%) | 0.496 |
SVR12 | 317 (98.1%) | 4 7(97.9%) | 82 (98.8%) | 32 (100%) | 156 (97.5%) | 0.759 |